Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins

Francesco Di Pierro,1 Iaele Bellone,2 Giuliana Rapacioli,3 Pietro Putignano4 1Scientific Department, Velleja Research, Milan, Italy; 2ASL TO1, Turin, Italy; 3AIOR, Pontenure, Province of Piacenza, Italy; 4University Hospital San Gerardo, Monza, Italy Background: Statin intolerance is a medical con...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Di Pierro F, Bellone I, Rapacioli G, Putignano P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/ca1167d22c7041eba6104ccd94fc6ed2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca1167d22c7041eba6104ccd94fc6ed2
record_format	dspace
spelling	oai:doaj.org-article:ca1167d22c7041eba6104ccd94fc6ed22021-12-02T09:22:18ZClinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins1178-7007https://doaj.org/article/ca1167d22c7041eba6104ccd94fc6ed22015-02-01T00:00:00Zhttp://www.dovepress.com/clinical-role-of-a-fixed-combination-of-standardized-berberis-aristata-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007 Francesco Di Pierro,1 Iaele Bellone,2 Giuliana Rapacioli,3 Pietro Putignano4 1Scientific Department, Velleja Research, Milan, Italy; 2ASL TO1, Turin, Italy; 3AIOR, Pontenure, Province of Piacenza, Italy; 4University Hospital San Gerardo, Monza, Italy Background: Statin intolerance is a medical condition often leading patients to nonadherence to the prescribed therapy or to a relevant reduction of the statin dosage. Both situations determine a totally or partially uncontrolled lipid profile, and these conditions unquestionably increase the risk of cardiovascular events. Methods: We enrolled hypercholesterolemic, type 2 diabetic patients complaining of intolerance to statins. Some of them had reduced the statin dose ‘until the disappearance of symptoms’; others had opted for treatment with ezetimibe; and yet others were not undergoing any treatment at all. All patients of the three groups were then given a fixed combination of berberine and silymarin (Berberol®), known from previous papers to be able to control both lipidic and glycemic profiles. Results: The tested product both as a single therapy and as add-on therapy to low-dose statin or to ezetimibe reduced triglycerides, low-density lipoprotein cholesterol, fasting blood glucose, and glycosylated hemoglobin in a significant manner without inducing toxicity conditions that might be somehow ascribed to a statin-intolerant condition. Conclusion: Our study demonstrates that use of Berberol®, administered as a single or add-on therapy in statin-intolerant subjects affected by diabetes and hypercholesterolemia is a safe and effective tool capable of improving the patients' lipidic and glycemic profiles. Keywords: berberine, silymarin, Berberol®, ezetimibe, cholesterol, type 2 diabetesDi Pierro FBellone IRapacioli GPutignano PDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 89-96 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Di Pierro F Bellone I Rapacioli G Putignano P Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins
description	Francesco Di Pierro,1 Iaele Bellone,2 Giuliana Rapacioli,3 Pietro Putignano4 1Scientific Department, Velleja Research, Milan, Italy; 2ASL TO1, Turin, Italy; 3AIOR, Pontenure, Province of Piacenza, Italy; 4University Hospital San Gerardo, Monza, Italy Background: Statin intolerance is a medical condition often leading patients to nonadherence to the prescribed therapy or to a relevant reduction of the statin dosage. Both situations determine a totally or partially uncontrolled lipid profile, and these conditions unquestionably increase the risk of cardiovascular events. Methods: We enrolled hypercholesterolemic, type 2 diabetic patients complaining of intolerance to statins. Some of them had reduced the statin dose ‘until the disappearance of symptoms’; others had opted for treatment with ezetimibe; and yet others were not undergoing any treatment at all. All patients of the three groups were then given a fixed combination of berberine and silymarin (Berberol®), known from previous papers to be able to control both lipidic and glycemic profiles. Results: The tested product both as a single therapy and as add-on therapy to low-dose statin or to ezetimibe reduced triglycerides, low-density lipoprotein cholesterol, fasting blood glucose, and glycosylated hemoglobin in a significant manner without inducing toxicity conditions that might be somehow ascribed to a statin-intolerant condition. Conclusion: Our study demonstrates that use of Berberol®, administered as a single or add-on therapy in statin-intolerant subjects affected by diabetes and hypercholesterolemia is a safe and effective tool capable of improving the patients' lipidic and glycemic profiles. Keywords: berberine, silymarin, Berberol®, ezetimibe, cholesterol, type 2 diabetes
format	article
author	Di Pierro F Bellone I Rapacioli G Putignano P
author_facet	Di Pierro F Bellone I Rapacioli G Putignano P
author_sort	Di Pierro F
title	Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins
title_short	Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins
title_full	Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins
title_fullStr	Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins
title_full_unstemmed	Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins
title_sort	clinical role of a fixed combination of standardized berberis aristata and silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/ca1167d22c7041eba6104ccd94fc6ed2
work_keys_str_mv	AT dipierrof clinicalroleofafixedcombinationofstandardizedberberisaristataandsilybummarianumextractsindiabeticandhypercholesterolemicpatientsintoleranttostatins AT bellonei clinicalroleofafixedcombinationofstandardizedberberisaristataandsilybummarianumextractsindiabeticandhypercholesterolemicpatientsintoleranttostatins AT rapaciolig clinicalroleofafixedcombinationofstandardizedberberisaristataandsilybummarianumextractsindiabeticandhypercholesterolemicpatientsintoleranttostatins AT putignanop clinicalroleofafixedcombinationofstandardizedberberisaristataandsilybummarianumextractsindiabeticandhypercholesterolemicpatientsintoleranttostatins
_version_	1718398148387274752

Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins

Ejemplares similares